Display options
Cite
Kawasaki K, Hamamoto Y, Suzuki T, et al. Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report. Oncol Lett. 2017;14(3):3697-3700doi: 10.3892/ol.2017.6601.
Kawasaki, K., Hamamoto, Y., Suzuki, T., Hirata, K., Sukawa, Y., Kasuga, A., Hayashi, Y., Takaishi, H., Kameyama, K., & Kanai, T. (2017). Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report. Oncology letters, 14(3), 3697-3700. https://doi.org/10.3892/ol.2017.6601
Kawasaki, Kenta, et al. "Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report." Oncology letters vol. 14,3 (2017): 3697-3700. doi: https://doi.org/10.3892/ol.2017.6601
Kawasaki K, Hamamoto Y, Suzuki T, Hirata K, Sukawa Y, Kasuga A, Hayashi Y, Takaishi H, Kameyama K, Kanai T. Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report. Oncol Lett. 2017 Sep;14(3):3697-3700. doi: 10.3892/ol.2017.6601. Epub 2017 Jul 18. PMID: 28927133; PMCID: PMC5587936.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Sep;14(3):3697-3700. doi: 10.3892/ol.2017.6601. Epub 2017 Jul 18.

Benefit of rebiopsy for deciding treatment strategy in rectal cancer: A case report.

Oncology letters

Kenta Kawasaki, Yasuo Hamamoto, Takeshi Suzuki, Kenro Hirata, Yasutaka Sukawa, Akiyoshi Kasuga, Yuichiro Hayashi, Hiromasa Takaishi, Kaori Kameyama, Takanori Kanai

Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.
  2. Keio Cancer Center, Keio University School of Medicine, Tokyo 160-8582, Japan.
  3. Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo 160-8582, Japan.

PMID: 28927133 PMCID: PMC5587936 DOI: 10.3892/ol.2017.6601

Abstract

Rebiopsy is considered an option for specific types of cancer, such as breast, non-small cell lung, and prostate cancer, in clinical trials and in practice. The benefit of rebiopsy comes from the selection of a new treatment strategy based on the genetic profile of the cells, which may reflect the development of drug resistance or hormonal changes. For colorectal cancer, the presence of different genomic mutations between the primary tumor and its metastases is rare, and rebiopsy is therefore not generally performed. The present study reports the case of a 68-year-old man who was initially diagnosed with metastatic adenocarcinoma from a primary colorectal cancer, but was subsequently rediagnosed with metastatic neuroendocrine carcinoma based on the pathological rebiopsy results. The patient responded well to cisplatin and etoposide treatment, after not responding to initial FOLFOX treatment. In this case, rebiopsy resulted in a change in treatment regimen and improved the patient's quality of life and his long-term survival. This case indicates that, when a colorectal cancer patient is unresponsive to standard treatment, it may be beneficial for the clinician to suspect an atypical histological type, and to consider rebiopsy.

Keywords: biopsy; colorectal cancer; neuroendocrine cancer

References

  1. Mol Pathol. 2003 Jun;56(3):137-40 - PubMed
  2. Ann Oncol. 2014 Oct;25(10):1871-88 - PubMed
  3. J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 - PubMed
  4. Dis Colon Rectum. 2015 Mar;58(3):294-303 - PubMed
  5. Semin Oncol. 2007 Feb;34(1):22-9 - PubMed
  6. Am J Surg Pathol. 2002 Jul;26(7):863-72 - PubMed
  7. J Clin Oncol. 2014 Oct 20;32(30):3360-4 - PubMed
  8. J Clin Oncol. 2001 Jun 1;19(11):2837-43 - PubMed
  9. J Clin Oncol. 2012 Dec 20;30(36):e386-9 - PubMed
  10. Oncologist. 2011;16(9):1239-49 - PubMed
  11. J Cancer Res Clin Oncol. 2007 Oct;133(10):783-5 - PubMed
  12. Dis Colon Rectum. 2004 Feb;47(2):163-9 - PubMed
  13. Curr Oncol Rep. 2011 Feb;13(1):17-25 - PubMed
  14. Science. 2014 Dec 19;346(6216):1480-6 - PubMed
  15. J Clin Oncol. 2015 Aug 20;33(24):2695-704 - PubMed
  16. Virchows Arch. 2010 Nov;457(5):521-7 - PubMed
  17. Lung Cancer. 2014 Nov;86(2):170-3 - PubMed
  18. Lung Cancer. 2013 Nov;82(2):294-8 - PubMed
  19. Biochem Biophys Res Commun. 2004 Dec 17;325(3):784-91 - PubMed
  20. Cancer Treat Rev. 2012 Oct;38(6):708-14 - PubMed
  21. Ann Oncol. 2014 Sep;25 Suppl 3:iii27-39 - PubMed
  22. Ann Oncol. 2009 Sep;20(9):1499-504 - PubMed

Publication Types